poisar

Stock

Verastem, Inc. VSTM

$6.89+1.03%

Overview

VSTM market data

Price History

VSTM price chart · 1M
O
6.85
H
7.02
L
6.84
C
6.89
Vol
74,916.00
Source
US equities market feed
Observed
Aug 21, 2026, 12:00 AM
Cadence
Five-minute page cache; daily and stored hourly bars
Status
fresh

Key Stats & Performance

Open
$6.85
Previous Close
$6.82
Day High
$7.02
Day Low
$6.84
52 Week High
$7.86
52 Week Low
$3.43
7 Day Return
+4.63%
30 Day Return
+16.58%
90 Day Return
+58.03%
1 Year Return
+21.30%
Daily Notional Volume
$516.2K
Latest daily bar volume multiplied by its closing price.

Valuation & Profitability

Provider-backed
P/E (TTM)
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
-$3.02
Diluted earnings per share over the trailing twelve months.
Beta
0.48
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
-391.2%
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$3.43 – $11.25
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · market cap $586.1M · P/B 10.17 · P/S 11.82.

Company News

10 captured
Mizuho Maintains Outperform on Verastem, Lowers Price Target to $13Benzinga · Aug 11, 2026, 11:48 AM
Guggenheim Maintains Buy on Verastem, Lowers Price Target to $12Benzinga · Aug 7, 2026, 4:46 PM
Verastem shares are trading higher after the company reported better-than-expected Q2 financial results.Benzinga · Aug 7, 2026, 12:40 PM
8-K filing — Verastem, Inc. (VSTM)SEC EDGAR · Aug 6, 2026, 11:33 PM
Verastem Q2 Adj. EPS $(0.35) Beats $(0.43) Estimate, Sales $25.078M Beat $23.093M EstimateBenzinga · Aug 6, 2026, 8:05 PM
Verastem Oncology Doses First Participant In Its TARGET-D 203 Phase 2 Study Of VS-7375 To Treat Metastatic Colorectal CancerBenzinga · Jul 28, 2026, 8:02 PM
12 Health Care Stocks Moving In Thursday's After-Market SessionBenzinga · Jul 23, 2026, 9:10 PM
Verastem Oncology Doses First Patient In Phase 2 Trial Of VS-7375 For KRAS G12D-Mutated Advanced Non-Small Cell Lung Cancer And Untreated Asymptomatic Untreated Brain MetastasesBenzinga · Jul 22, 2026, 8:02 PM
These 7 Small Caps Are on Fire as the Second Half Begins: Here’s WhyBenzinga · Jul 21, 2026, 7:52 PM
RBC Capital Maintains Outperform on Verastem, Lowers Price Target to $14Benzinga · Jul 7, 2026, 4:25 PM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock